Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS).
The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and Regeneron. New-York based Regeneron (US) has had a long-lived and healthy collaboration with France’s Sanofi since 2007, sharing monoclonal antibody research for R&D in several fields.
Praluent (alirocumab) is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which reduces the amount of low-density cholesterol produced in the liver. Marketed to the US for patients who are also taking statins, the EU license (issued in September) permits marketing of Praluent to the same demographic. In completed trials, Praluent reduced LDL cholesterol by up to an additional 62 percent versus placebo, and was generally well-tolerated with an acceptable safety profile.